Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Low-dose gemcitabine for advanced CTCL

Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the clinical outcomes of patients with advanced-stage cutaneous (CTCL) lymphoma who are treated with low-dose gemcitabine. Dr Assaf describes how high-doses are associated with severe side effects, often resulting in discontinuation, leading to investigations into the efficacy of low-dose gemcitabine. Dr Assaf reports that low-dose gemcitabine has been shown to achieve a similar response rate to high-dose gemcitabine, and is also able to achieve similar or even longer durations of response. Dr Assaf also comments on potential benefits of using low-dose gemcitabine in combination with mogamulizumab or brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.